Pneumovax 23 Description
Merck's Pneumovax 23 (Pneumococcal Vaccine Polyvalent) is a vaccine that can help protect against infection by 23 types of pneumococcal bacteria, which are common and often cause serious illnesses.
Pneumovax 23 vaccine contains 23 serotypes (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F).
Pneumovax 23 Indication
The pneumococcal disease includes pneumococcal infections of the lung, blood, and coverings of the brain and spinal cord. Pneumovax 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine.
Do not administer Pneumovax 23 to individuals with a history of a hypersensitivity reaction to any component of the vaccine.
Additionally, the U.S. CDC recommends Pneumovax 23 for people who have certain chronic conditions such as diabetes, heart disease, or COPD and who are 19 to 64 years old.
The global prevalence of the pneumococcal disease, an infection caused by bacteria called Streptococcus pneumoniae, is evolving, says the CDC. Highly aggressive strains, or serotypes, threaten to put more people at risk for non-invasive pneumococcal illnesses such as pneumonia (when it is confined to the lungs), sinusitis, and otitis media (middle ear infection); and invasive pneumococcal illnesses such as bacteremia (infection in the bloodstream), bacteremic pneumonia (pneumonia with bacteremia) and meningitis.
Pneumovax 23 Dosage
Pneumovax 23 is administered as an intramuscular or subcutaneous injection only.
Pneumovax 23 is for people 50 years of age and older and is approved for persons aged ≥2 years who are at increased risk for pneumococcal disease. And if you are 65 years or older, even if you already had a dose of another vaccine before 65 for pneumococcal pneumonia, the U.S. CDC recommends you get Pneumovax 23.
The most common adverse reactions, reported in >10% of subjects vaccinated with PNEUMOVAX 23 in clinical trials, were: injection-site pain/soreness/tenderness, injection-site swelling/induration, headache, injection-site erythema, asthenia and fatigue, and myalgia.
Pneumovax 23 News
October 23, 2020 - A case-control test-negative design study: Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults.
July 20, 2020 - Time for a third-generation pneumococcal conjugate vaccine.
June 22, 2020 - Merck announced results from two initial Phase 3 studies evaluating the safety, tolerability, and immunogenicity of V114, the company’s investigational 15-valent pneumococcal conjugate vaccine. These data, in addition to results from V110-029, a study evaluating PNEUMOVAX ® 23 in healthy adults 50 years of age or older, were published via the International Symposium on Pneumococci and Pneumococcal Diseases online digital library.
January 31, 2020 - Updated Pneumococcal Vaccine Recommendations for Older Adults.
November 26, 2019 - 'We have approved your request submitted and received June 4, 2019, to supplement your Biologics License Application (BLA) under section 351(a) of the Public Health Service Act for Pneumococcal Vaccine Polyvalent (PNEUMOVAX®23) manufactured at West Point, Pennsylvania.